Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System

Pfizer IncPfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods. Nearly 60 percent of physicians who responded to the survey also agreed that adverse event reporting through an EHR system would improve patient care.

"Patient safety continues to be a top priority at Pfizer," said Freda Lewis-Hall, MD, Pfizer’s chief medical officer. "This survey furthers our understanding about how we can best use electronic health records systems to collect critical information about the safe and appropriate use of our products so that we can improve patient safety."

Of the 300 physicians surveyed, two-thirds utilized some form of an EHR system and one-third used a paper-based system. Half of all respondents and 60 percent of fully-functional EHR users reported that they would be much more likely to submit information about adverse events using an EHR system. Of those still using paper-based systems, 80 percent cited cost as a deterrent to investing in an EHR system.

Ipsos conducted the survey online among primary care physicians in the United States who were categorized as basic electronic health record users, fully functional electronic health record users or paper health record users. The research was conducted during September and October 2009.

As part of the company's ongoing efforts to improve patient safety, Pfizer is collaborating with Brigham and Women's Hospital, Partners Healthcare, CDISC, an international standards group, and CRIX International to improve the quality of data in safety reports. Earlier this year, the group conducted a pilot known as the ASTER (Adverse Drug Event Spontaneous Triggered Event Reporting) study, allowing physicians to use electronic health records to report adverse events directly to the Food and Drug Administration (FDA). By exploring a combination of standards, technology and a new business model, the group intends to help physicians better recognize and report adverse events.

"These survey results confirm what we saw in the Partners Healthcare ASTER study," said Jeffrey A. Linder, MD, MPH, FACP an internist at Brigham and Women's Hospital in Boston. "The system we used in that study was well accepted by the participating physicians, who felt the adverse event reporting was unobtrusive and who saw the public health potential of this type of reporting. While most of the participating clinicians submitted no reports in the year prior to the study, they submitted hundreds of detailed reports during the five months of the study period."

Physician-reported adverse events are critical to the safety profiles of products by FDA. In the current adverse event reporting process, it can take physicians as long as 40 minutes to fill out required paperwork. By transitioning to an electronic health record system for reporting these events to the FDA, the process is completed in a matter of minutes. For physicians, it is important for EHR adverse event reporting to be easy to use, convenient and safe for patients.

"Adverse event reports are a key component of our ongoing efforts in patient safety," said Dr. Lewis-Hall. "One critical goal is to increase the number and quality of the reports we receive. By making it easier and more convenient for doctors, we anticipate meeting this goal. ASTER is an impressive step in demonstrating how we can leverage EHRs to do just that."

Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]